{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:04:14Z","timestamp":1784905454606,"version":"3.55.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["1PO1HL131477"],"award-info":[{"award-number":["1PO1HL131477"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["R01HL150078"],"award-info":[{"award-number":["R01HL150078"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006537","name":"Vanderbilt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01BX005991"],"award-info":[{"award-number":["I01BX005991"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["R56DK138826"],"award-info":[{"award-number":["R56DK138826"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["NIDDK R56"],"award-info":[{"award-number":["NIDDK R56"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.isci.2025.114079","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:00:44Z","timestamp":1763640044000},"page":"114079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["IFN\u03b3 signaling drives resistance to FLT3 inhibition in acute myeloid leukemia"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6086-7656","authenticated-orcid":false,"given":"Abraheem","family":"Khouqeer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Cartailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad R.","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Welner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-9154","authenticated-orcid":false,"given":"P. Brent","family":"Ferrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.114079_bib1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?","volume":"2013","author":"Levis","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.isci.2025.114079_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1365-2141.2003.04500.x","article-title":"Flt3 mutations and leukaemia","volume":"122","author":"Kottaridis","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.isci.2025.114079_bib3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.isci.2025.114079_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.114079_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"O\u2019Donnell","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.isci.2025.114079_bib6","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: Current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2025.114079_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A Review of FLT3 Inhibitors in Acute Myeloid Leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.isci.2025.114079_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2025.114079_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12185-023-03681-0","article-title":"FLT3 targeting in the modern era: from clonal selection to combination therapies","volume":"120","author":"Kennedy","year":"2024","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.isci.2025.114079_bib10","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/s41467-024-45916-6","article-title":"Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.114079_bib11","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.3390\/cancers16233974","article-title":"Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia","volume":"16","author":"Naji","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2025.114079_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz0463","article-title":"Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia","volume":"12","author":"Vadakekolathu","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2025.114079_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114079_bib14","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2019003124","article-title":"Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia","volume":"136","author":"Gebru","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114079_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41375-022-01789-6","article-title":"Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed\/refractory acute myeloid leukemia","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.114079_bib16","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","article-title":"Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL","volume":"104","author":"Dumas","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2025.114079_bib17","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.18632\/oncotarget.2542","article-title":"AXL kinase as a novel target for cancer therapy","volume":"5","author":"Wu","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2025.114079_bib18","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","article-title":"Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma","volume":"122","author":"Ben-Batalla","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114079_bib19","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/leu.2015.147","article-title":"Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia","volume":"29","author":"Park","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.114079_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30467-w","article-title":"A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer","volume":"8","author":"Howard","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114079_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s40659-019-0220-0","article-title":"Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell lines","volume":"52","author":"Viscarra","year":"2019","journal-title":"Biol. Res."},{"key":"10.1016\/j.isci.2025.114079_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3390\/cells13050388","article-title":"Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death","volume":"13","author":"Sazonova","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.isci.2025.114079_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fonc.2014.00040","article-title":"In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies","volume":"4","author":"McDermott","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2025.114079_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nm.3841","article-title":"Studying clonal dynamics in response to cancer therapy using high-complexity barcoding","volume":"21","author":"Bhang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2025.114079_bib25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-20-1265","article-title":"Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer","volume":"12","author":"Chang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2025.114079_bib26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.molcel.2020.10.005","article-title":"Activation of Clustered IFN\u03b3 Target Genes Drives Cohesin-Controlled Transcriptional Memory","volume":"80","author":"Siwek","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114079_bib27","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-09-528752","article-title":"TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis","volume":"123","author":"van der Meer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.114079_bib28","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1073\/pnas.111163898","article-title":"Biologic consequences of Stat1-independent IFN signaling","volume":"98","author":"Gil","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2025.114079_bib29","article-title":"STAT1 deficiency redirects IFN signalling toward suppression of TLR response through a feedback activation of STAT3","volume":"5","author":"Kim","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114079_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2025.114079_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40164-024-00566-8","article-title":"AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies","volume":"13","author":"Vandewalle","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.114079_bib32","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3389\/fimmu.2017.01139","article-title":"Deciphering of the Human Interferon-Regulated Proteome by Mass Spectrometry-Based Quantitative Analysis Reveals Extent and Dynamics of Protein Induction and Repression","volume":"8","author":"Megger","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2025.114079_bib33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/leu.2013.205","article-title":"Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)","volume":"28","author":"Zhou","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.114079_bib34","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer","volume":"70","author":"Holland","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2025.114079_bib35","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1021\/bi00379a034","article-title":"Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation","volume":"26","author":"Yarden","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.isci.2025.114079_bib36","doi-asserted-by":"crossref","first-page":"11987","DOI":"10.1074\/jbc.273.20.11987","article-title":"Autoregulatory mechanisms in protein-tyrosine kinases","volume":"273","author":"Hubbard","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2025.114079_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.114079_bib38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41586-023-06342-8","article-title":"Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells","volume":"620","author":"Goyal","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.114079_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cell.2020.07.003","article-title":"Memory Sequencing Reveals Heritable Single-Cell Gene Expression Programs Associated with Distinct Cellular Behaviors","volume":"182","author":"Shaffer","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.114079_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48256-4","article-title":"Myeloid maturation potentiates STAT3-mediated atypical IFN-\u03b3 signaling and upregulation of PD-1 ligands in AML and MDS","volume":"9","author":"Yoyen-Ermis","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.114079_bib41","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/10245332.2018.1486064","article-title":"Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia","volume":"23","author":"Wang","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.isci.2025.114079_bib42","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-20-3114","article-title":"Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia","volume":"27","author":"Dumas","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2025.114079_bib43","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1038\/sj.onc.1201865","article-title":"Determinants for transformation induced by the Axl receptor tyrosine kinase","volume":"16","author":"Burchert","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2025.114079_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2025.114079_bib45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/2767-9764.CRC-23-0357","article-title":"Spectral Flow Cytometry Methods and Pipelines for Comprehensive Immunoprofiling of Human Peripheral Blood and Bone Marrow","volume":"4","author":"Spasic","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.isci.2025.114079_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-Response Analysis Using R","volume":"10","author":"Ritz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2025.114079_bib47","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gr.209601.116","article-title":"UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy","volume":"27","author":"Smith","year":"2017","journal-title":"Genome Res."},{"key":"10.1016\/j.isci.2025.114079_bib48","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2025.114079_bib49","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2025.114079_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-4939-6527-4_10","article-title":"Establishment and Characterization of Long-Term Cultures Derived from Primary Acute Myeloid Leukemia Cells for HDAC Inhibitor Research","volume":"1510","author":"Romanski","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.isci.2025.114079_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw3381","article-title":"Lineage tracing on transcriptional landscapes links state to fate during differentiation","volume":"367","author":"Weinreb","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.isci.2025.114079_bib52","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2016.02.012","article-title":"Resources for the comprehensive discovery of functional RNA elements","volume":"61","author":"Sundararaman","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2025.114079_bib53","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","article-title":"The nf-core framework for community-curated bioinformatics pipelines","volume":"38","author":"Ewels","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2025.114079_bib54","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nbt.3820","article-title":"Nextflow enables reproducible computational workflows","volume":"35","author":"Di Tommaso","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2025.114079_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100530","article-title":"A protocol for rapid degradation of endogenous transcription factors in mammalian cells and identification of direct regulatory targets","volume":"2","author":"Layden","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.isci.2025.114079_bib56","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4161\/cc.8.3.7701","article-title":"Single-vector inducible lentiviral RNAi system for oncology target validation","volume":"8","author":"Wiederschain","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.isci.2025.114079_bib57","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/s41467-022-29383-5","article-title":"cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies","volume":"13","author":"Pedersen","year":"2022","journal-title":"Nat. Commun."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225023405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225023405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:50:19Z","timestamp":1783475419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225023405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2589004225023405"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.114079","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN\u03b3 signaling drives resistance to FLT3 inhibition in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.114079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114079"}}